...
首页> 外文期刊>Drug delivery and translational research >Preparation and characterization of metoprolol tartrate containing matrix type transdermal drug delivery system
【24h】

Preparation and characterization of metoprolol tartrate containing matrix type transdermal drug delivery system

机译:含有基质透皮药物递送系统的甲状腺罗酚酒桶的制备与表征

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The present study aimed to develop matrix-type transdermal drug delivery system (TDDS) of metoprolol tartrate using polyvinyl pyrrolidone (PVP) and polyvinyl alcohol (PVA). The transdermal films were evaluated for physical parameters, Fourier transform infrared spectroscopy analysis (FTIR), differential scanning calorimetry (DSC), in vitro drug release, in vitro skin permeability, skin irritation test and stability studies. The films were found to be tough, non-sticky, easily moldable and possess good tensile strength. As the concentration of PVAwas increased, the tensile strength of the films was also increased. Results of FTIR spectroscopy and DSC revealed the absence of any drug-polymer interactions. In vitro release of metoprolol followed zero-order kinetics and the mechanism of release was found to be diffusion rate controlled. In vitro release studies of metoprolol using Keshary-Chein (vertical diffusion cell) indicated 65.5 % drug was released in 24 h. In vitro skin permeation of metoprolol transdermal films showed 58.13 % of the drug was released after 24 h. In vitro skin permeation of metoprolol followed zero-order kinetics in selected formulations. The mechanism of release was found to be diffusion rate controlled. In a 22-day skin irritation test, tested formulation of transdermal films did not exhibit any allergic reactions, inflammation, or contact dermatitis. The transdermal films showed good stability in the 180-day stability study. It can be concluded that the TDDS of MPT can help in bypassing the first-pass effect and will provide patient improved compliance, without sacrificing the therapeutic advantages of the drugs.
机译:本研究旨在使用聚乙烯吡咯烷酮(PVP)和聚乙烯醇(PVA)发育富含托洛尔替代药物的基质透皮药物输送系统(TDDS)。评价透皮膜的物理参数,傅里叶变换红外光谱分析(FTIR),差示扫描量热法(DSC),体外药物释放,体外皮肤渗透性,皮肤刺激性试验和稳定性研究。发现薄膜坚固,不粘,可模塑,具有良好的拉伸强度。随着PVAWA的浓度增加,薄膜的拉伸强度也增加。 FTIR光谱和DSC的结果显示不存在任何药物聚合物相互作用。体外释放美托洛尔脱落,零级动力学和释放机制被发现是扩散速率控制。使用keshary-chein(垂直扩散细胞)的氟洛尔酚的体外释放研究表明,24小时释放了65.5%的药物。在体外皮肤渗透透皮膜的透射膜显示出58.13%的药物在24小时后释放。体外皮肤渗透美托洛尔培养均在所选配方中的零级动力学。发现释放机制是控制的扩散速率。在22天的皮肤刺激试验中,测试的透皮膜的制剂没有表现出任何过敏反应,炎症或接触皮炎。透皮膜在180天的稳定性研究中表现出良好的稳定性。可以得出结论,MPT的TDDS可以帮助绕过一级效应,并将提供患者改善的合规性,而不会牺牲药物的治疗优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号